Clinically actionable targets and active inhibitors against targets in cancer cells have been demonstrated2, and small-molecule inhibitors have been approved by the US Food and Drug Administration (FDA) for use against tumor cells with addicted oncogenes, including HER2, ALK, BRAF, and EGFR3. This evidence concerns the gene BRAF and cancer.